Since 2020, vaccine development and evidence-based evaluation by national immunization technical advisory groups (NITAGs) and health technology assessment (HTA) agencies have become important line items in pharmaceutical investment and strategic planning. Now more than ever, HEOR and market access teams need to ensure they have a deep understanding of vaccine evaluation requirements to plan for success. During this presentation we will analyze the global requirements of NITAGs and HTA agencies for vaccine evaluation, and discuss how you can provide your team with the materials they need to demonstrate value.
- Understand which stakeholders are involved in vaccine evaluation, and global NITAG and HTA requirements.
- Consider differences in vaccine modeling requirements among markets
- Explore how to develop global value dossiers that meet the needs of NITAGs and HTA agencies.